Timber Creek Capital Management LLC Lowers Position in Eli Lilly and Company (NYSE:LLY)

Timber Creek Capital Management LLC trimmed its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 14.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,558 shares of the company’s stock after selling 2,041 shares during the period. Eli Lilly and Company comprises about 3.1% of Timber Creek Capital Management LLC’s investment portfolio, making the stock its 9th largest position. Timber Creek Capital Management LLC’s holdings in Eli Lilly and Company were worth $9,770,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Buckhead Capital Management LLC boosted its position in shares of Eli Lilly and Company by 0.7% during the fourth quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock worth $1,226,000 after buying an additional 15 shares during the period. Levin Capital Strategies L.P. boosted its position in shares of Eli Lilly and Company by 3.8% during the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock worth $242,000 after buying an additional 15 shares during the period. Clearwater Capital Advisors LLC boosted its position in shares of Eli Lilly and Company by 1.3% during the fourth quarter. Clearwater Capital Advisors LLC now owns 1,202 shares of the company’s stock worth $701,000 after buying an additional 15 shares during the period. JGP Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 0.9% during the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after buying an additional 16 shares during the period. Finally, Claret Asset Management Corp boosted its position in shares of Eli Lilly and Company by 3.3% during the fourth quarter. Claret Asset Management Corp now owns 494 shares of the company’s stock worth $288,000 after buying an additional 16 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. Jefferies Financial Group increased their price target on Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Bank of America increased their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. BMO Capital Markets increased their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Finally, The Goldman Sachs Group increased their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $787.53.

Check Out Our Latest Analysis on LLY

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the transaction, the insider now owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the transaction, the executive vice president now owns 25,428 shares in the company, valued at approximately $20,835,194.64. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the sale, the insider now directly owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 762,804 shares of company stock worth $648,109,138. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $891.46 on Wednesday. The firm has a market cap of $847.25 billion, a P/E ratio of 131.29, a price-to-earnings-growth ratio of 1.93 and a beta of 0.36. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 1-year low of $434.34 and a 1-year high of $894.87. The business’s 50 day moving average is $790.79 and its 200-day moving average is $723.56.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.62 earnings per share. Equities research analysts predict that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were paid a dividend of $1.30 per share. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.